DE69113795D1 - Steroid 5-alpha-reduktase. - Google Patents

Steroid 5-alpha-reduktase.

Info

Publication number
DE69113795D1
DE69113795D1 DE69113795T DE69113795T DE69113795D1 DE 69113795 D1 DE69113795 D1 DE 69113795D1 DE 69113795 T DE69113795 T DE 69113795T DE 69113795 T DE69113795 T DE 69113795T DE 69113795 D1 DE69113795 D1 DE 69113795D1
Authority
DE
Germany
Prior art keywords
preparation
steroid
alpha
disclosed
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69113795T
Other languages
English (en)
Other versions
DE69113795T2 (de
Inventor
Stefan Andersson
David Russell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Application granted granted Critical
Publication of DE69113795D1 publication Critical patent/DE69113795D1/de
Publication of DE69113795T2 publication Critical patent/DE69113795T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/001Oxidoreductases (1.) acting on the CH-CH group of donors (1.3)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y103/00Oxidoreductases acting on the CH-CH group of donors (1.3)
    • C12Y103/01Oxidoreductases acting on the CH-CH group of donors (1.3) with NAD+ or NADP+ as acceptor (1.3.1)
    • C12Y103/010223-Oxo-5alpha-steroid 4-dehydrogenase (NADP+) (1.3.1.22), i.e. cortisone alpha-reductase
DE69113795T 1990-04-30 1991-04-25 Steroid 5-alpha-reduktase. Expired - Fee Related DE69113795T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51766190A 1990-04-30 1990-04-30
PCT/US1991/002866 WO1991017251A1 (en) 1990-04-30 1991-04-25 STEROID 5α-REDUCTASES

Publications (2)

Publication Number Publication Date
DE69113795D1 true DE69113795D1 (de) 1995-11-16
DE69113795T2 DE69113795T2 (de) 1996-03-28

Family

ID=24060703

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69113795T Expired - Fee Related DE69113795T2 (de) 1990-04-30 1991-04-25 Steroid 5-alpha-reduktase.

Country Status (8)

Country Link
US (2) US5422262A (de)
EP (1) EP0528906B1 (de)
JP (1) JP3294844B2 (de)
AT (1) ATE129013T1 (de)
AU (1) AU642501B2 (de)
CA (1) CA2079454C (de)
DE (1) DE69113795T2 (de)
WO (1) WO1991017251A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2079454C (en) * 1990-04-30 2002-02-26 Stefan Andersson Steroid 5.alpha.-reductases
US5576191A (en) * 1994-06-17 1996-11-19 Immunex Corporation Cytokine that binds ST2
US5656613A (en) * 1995-01-04 1997-08-12 Merck & Co., Inc. Treatment of hyperandrogenic conditions
US20020170077A1 (en) * 1995-02-10 2002-11-14 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease
US5968770A (en) * 1995-02-10 1999-10-19 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd523 as a target
US6359194B1 (en) 1995-02-10 2002-03-19 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease
IT1276662B1 (it) * 1995-04-04 1997-11-03 Uni Degli Studi Camerino Vaccini polinucleotidici
CA2243508A1 (en) * 1995-12-07 1997-06-12 Baylor College Of Medicine Urogenital sinus derived growth factor nucleotide and amino acid sequences
CA2247246A1 (en) 1996-02-16 1997-08-21 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease
AU2666797A (en) * 1996-04-15 1997-11-07 Dyad Pharmaceutical Corporation Combination therapy for androgenic alopecia with antisense oligonucleotides and minoxidil
US6143950A (en) 1996-04-18 2000-11-07 The Salk Institute For Biological Studies Plant steroid 5α reductase, DET2
WO1997043313A1 (en) * 1996-05-15 1997-11-20 Byk Gulden Lomberg Chemische Fabrik Gmbh Process for separating and analyzing hydrophobic proteins using thin layer chromatography
AU2238499A (en) 1998-01-23 1999-08-09 University Of Southern California Androgen-metabolic gene mutations and prostate cancer risk
ES2347027T3 (es) 1998-05-22 2010-10-22 The Board Of Trustees Of The Leland Stanford Junior University Moleculas bifuncionales y terapias basadas en las mismas.
EP1280915A1 (de) * 2000-04-13 2003-02-05 Millennium Pharmaceuticals, Inc. Menschliche 5-alpha reductase und deren anwendungen
US6469150B1 (en) * 2000-05-22 2002-10-22 Pharmacopeia, Inc. Cloning and characterization of genes encoding bradykinin B1 receptor homologues from five mammalian species
BR0115245A (pt) * 2000-10-30 2005-05-10 Pharmacia Corp 11 alfa-hidroxilase e óxido redutase de aspergillus ochraceus
ES2289002T3 (es) * 2000-11-09 2008-02-01 Astrazeneca Ab Composicion farmaceutica oral que contiene un copolimero de bloques.
JP2002236307A (ja) * 2001-02-09 2002-08-23 Asahi Optical Co Ltd ズームストロボ装置
US7635598B2 (en) * 2004-07-08 2009-12-22 Biosearch Technologies, Inc. Inducible fluorescence assay
US20070036740A1 (en) * 2004-10-06 2007-02-15 Reed Kenneth C Modulation of hair growth
EP2392258B1 (de) 2005-04-28 2014-10-08 Proteus Digital Health, Inc. Pharma-Informatiksystem
JP2009508494A (ja) 2005-09-16 2009-03-05 ラプトール ファーマシューティカル インコーポレイテッド Crを含むタンパク質に対して特異的な受容体−結合タンパク質(rap)変異体を含む組成物およびその使用
FR2903999B1 (fr) * 2006-07-19 2008-09-05 Galderma Res & Dev S N C Snc Modulateurs de sc4mol dans le traitement de l'acne ou de l'hyperseborrhee
EP2398500B1 (de) 2009-02-20 2019-03-13 2-BBB Medicines B.V. Arzneiabgabesystem auf glutathion-basis
US20120156138A1 (en) * 2009-04-14 2012-06-21 Smith Larry J Methods and Compositions for the Treatment of Medical Conditions Involving Cellular Reprogramming
MY163048A (en) 2009-05-06 2017-08-15 Laboratory Skin Care Inc Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2079454C (en) * 1990-04-30 2002-02-26 Stefan Andersson Steroid 5.alpha.-reductases

Also Published As

Publication number Publication date
US5679521A (en) 1997-10-21
WO1991017251A1 (en) 1991-11-14
AU642501B2 (en) 1993-10-21
ATE129013T1 (de) 1995-10-15
EP0528906A1 (de) 1993-03-03
EP0528906B1 (de) 1995-10-11
US5422262A (en) 1995-06-06
JPH05507405A (ja) 1993-10-28
CA2079454A1 (en) 1991-10-31
DE69113795T2 (de) 1996-03-28
JP3294844B2 (ja) 2002-06-24
AU7857991A (en) 1991-11-27
CA2079454C (en) 2002-02-26

Similar Documents

Publication Publication Date Title
ATE129013T1 (de) Steroid 5-alpha-reduktase.
Normington et al. Tissue distribution and kinetic characteristics of rat steroid 5 alpha-reductase isozymes. Evidence for distinct physiological functions.
Mortelmans et al. Defective thymine dimer excision by cell-free extracts of xeroderma pigmentosum cells.
DK1115874T3 (da) Alzheimer's sygdom-sekretase
DE69512219T2 (de) Gezielte spaltung von rns mittels gezielter bindung der ribonuklease p und spaltungssequenzen
DE69503129D1 (de) Pteridin-nukleotidderivate als fluoreszierende sonden
Champoux et al. The effects of camptothecin on the reaction and the specificity of the wheat germ type I topoisomerase
ATE309980T1 (de) Zubereitungen zur verwendung als therapeutische und nachweismittel
Wohl et al. Comparison of the esterase and human plasminogen activator activities of various activated forms of human plasminogen and their equimolar streptokinase complexes.
Katz et al. Estrogen-dependent trypsin-like activity in the rat uterus: localization of activity in the 12,000 g pellet and nucleus
Riendeau et al. Evidence for a fatty acid reductase catalyzing the synthesis of aldehydes for the bacterial bioluminescent reaction. Resolution from luciferase and dependence on fatty acids.
Dizdaroglu et al. A novel DNA N-glycosylase activity of E. coli T4 endonuclease V that excises 4, 6-diamino-5-formamidopyrimidine from DNA, a UV-radiation-and hydroxyl radical-induced product of adenine
MXPA02010868A (es) Secuencias de nucleotidos involucrados en el incremento o disminucion en la ovulacion mamifera.
AU2002257284A1 (en) Pna probes, probe sets, methods and kits pertaining to the detection of candida
Breimer A DNA glycosylase for oxidized thymine residues in Drosophilamelanogaster
Katz et al. Estradiol esters can replace 17β-estradiol in the stimulation of DNA and esterase synthesis by MCF-7 cells: a possible role for the estrogen-sensitive MCF-7 cell esterase
Van Nest et al. Effects of dexamethasone and 5-bromodeoxyuridine on protein synthesis and secretion during in vitro pancreatic development
Todhunter et al. Modification of rat liver RNA polymerase I after in vivo stimulation by hydrocortisone or methylisobutylxanthine
US7501273B2 (en) Peptidylarginine deiminase 6
Andersson et al. Steroid 5A reductase nucleic acid segments and recombinant vectors and host cells
AU2002304693A1 (en) Peptidylarginine deiminase 6
Eichler et al. Effect of human placental ribonuclease inhibitor in cell-free ribosomal RNA synthesis
Berman The roles of steroid 5-alpha reductase in the development of the male urogenital tract.
Hall CYTOCHROMES P‐450 IN STEROIDOGENESIS: ARE THESE ENZYMES MORE SPECIFIC THAN THOSE OF DRUG METABOLISM?
MILLS et al. New androgen-stimulated proteins in the kidneys of female mice

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee